Provided by Tiger Trade Technology Pte. Ltd.

Aquestive Therapeutics Inc.

3.97
+0.02000.51%
Post-market: 3.90-0.0700-1.76%17:40 EST
Volume:1.74M
Turnover:6.87M
Market Cap:484.35M
PE:-5.71
High:4.01
Open:3.90
Low:3.86
Close:3.95
52wk High:7.55
52wk Low:2.12
Shares:122.00M
Float Shares:115.00M
Volume Ratio:0.83
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6953
EPS(LYR):-0.5089
ROE:148.50%
ROA:-25.50%
PB:-117.88
PE(LYR):-7.80

Loading ...

Aquestive Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Reuters
·
Yesterday

Aquestive Therapeutics to Present New Anaphylm Clinical Data at AAAAI Annual Meeting

Reuters
·
Feb 20

Aquestive Therapeutics Names Dr. Matthew Greenhawt Chief Medical Officer

Reuters
·
Feb 18

Press Release: Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

Dow Jones
·
Feb 18

NASD Most Active Issues

Dow Jones
·
Feb 03

What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?

Benzinga_recent_news
·
Feb 03

Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval

TIPRANKS
·
Feb 02

Aquestive CRL from FDA ‘clearing event,’ says Oppenheimer

TIPRANKS
·
Feb 02

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Artivion (AORT)

TIPRANKS
·
Feb 02

Aquestive Therapeutics Shares Gain 38.6%

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Shares Gain 35% Premarket

THOMSON REUTERS
·
Feb 02

BRIEF-Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For Anaphylm

Reuters
·
Feb 02

Aquestive's Application for Allergic Reaction Treatment Has Deficiencies, FDA Says

Dow Jones
·
Feb 02

US FDA declines to approve Aquestive's oral drug for allergic reactions

Reuters
·
Feb 02

Aquestive Therapeutics Inc: Plans to Request Rapid Review by FDA

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Inc - Deficiencies Limited to Packaging and Administration

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Inc - Company Expects to Resubmit as Early as Q3 2026

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Inc - Plans to Submit in Canada and EU by End of 2026

THOMSON REUTERS
·
Feb 02

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

GlobeNewswire
·
Feb 02

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Reuters
·
Feb 02